Catalyst Pharmaceutical Partners Initiates a Registration-Directed U.S. Phase II(b) Clinical Trial in Collaboration With The National Institute on Drug Abuse and Veteran’s Administration Cooperative Studies Program

CORAL GABLES, Fla., Nov. 18, 2010 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that in collaboration with the National Institute on Drug Abuse (NIDA) and the Veterans Administration (VA) Cooperative Studies Program, it has initiated a registration-directed U.S. Phase II(b) clinical trial of CPP-109 in patients with cocaine addiction. CPP-109, Catalyst’s version of vigabatrin, is an orally administered drug, which inhibits psychostimulant-induced dopamine release. CPP-109 is Catalyst’s lead compound to treat stimulant addiction.